Three-drug combo for untreated Waldenström's macroglobulinemia
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study combines a targeted pill (zanubrutinib) with a lower dose of a chemotherapy drug (bendamustine) and an antibody treatment to see if it works well for people with untreated Waldenström's macroglobulinemia. It aims to reduce side effects while still controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have Waldenström's macroglobulinemia and have not had standard chemotherapy yet, or had only very limited prior treatment.
- You have symptoms from the disease, like low blood counts, fever, night sweats, or weight loss.
- You are physically able to care for yourself (ECOG score of 0 to 2).
- Your blood counts and liver/kidney function meet the study's safety levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach for people with Waldenström macroglobulinemia who have already been on ibrutinib and are doing well but not completely better. It adds two more medicines (bendamustine and rituximab) to see if this combination can achieve a deeper response and allow you to stop treatment after a set period.
This study is testing a combination of two medicines (zanubrutinib and BR) as the first treatment for patients with Waldenström's macroglobulinemia. The goal is to see if this combination works well and is safe for people who have not been treated before.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
This study tests a combination of two oral medications (zanubrutinib and BGB-11417) for people with Waldenström macroglobulinemia that has returned or not improved after prior therapy. The goal is to see if this combination is safe and works better at controlling the disease.
This trial tests a combination of two targeted therapies for Waldenstrom macroglobulinemia that has come back or not responded to previous treatment. The combination aims to attack the cancer cells in two different ways and may be more effective than either drug alone.
Hear when a new Waldenström Macroglobulinemia (WM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.